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CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Tetramer-based quantification of cytomegalovirus (CMV)–specific CD81
T lymphocytes in T-cell–depleted stem cell grafts and after transplantation
may identify patients at risk for progressive CMV infection
Jan W. Gratama, Joost W. J. van Esser, Cor H. J. Lamers, Claire Tournay, Bob Lo¨wenberg, Reinder L. H. Bolhuis, and Jan J. Cornelissen
Recovery of cytomegalovirus (CMV)–
specific T-cell–mediated immunity after
allogeneic hematopoietic stem cell trans-
plantation (SCT) is critical for protection
against CMV disease. The study used
fluorochrome-conjugated tetrameric com-
plexes of HLA-A2 molecules loaded with
the immunodominant NLVPMVATV (NLV)
peptide derived from the CMV protein
pp65 to quantify A2-NLV–specific CD81 T
cells in partially T-cell–depleted grafts
administered to 27 HLA-A*02011 patients
and to monitor recovery of these T cells
during the first 12 months after SCT. None
of the 9 CMV-seronegative patients be-
came infected with CMV, whereas 14 of 18
CMV-seropositive patients developed
CMV antigenemia after SCT. CMV-sero-
positive recipients of grafts from CMV-
seronegative donors required more pre-
emptive treatment with ganciclovir (GCV)
than those of grafts from CMV-seroposi-
tive donors (3 [1-6] versus 1 [0-3] courses,
respectively; P 5 .009). The number of
A2-NLV–specific CD81 T cells in the grafts
correlated inversely with the number of
preemptive GCV courses administered
(r 5 20.61; P 5 .01). None of the 9 CMV-
seronegative patients mounted a CMV-
specific immune response as measured
by monitoring A2-NLV–specific CD81 T
cells after SCT. Thirteen of 14 CMV-
seropositive patients without CMV dis-
ease recovered these T cells. In spite of
preemptive GCV treatment, CMV disease
developed in 4 patients, who all failed to
recover A2-NLV–specific CD81 T cells af-
ter SCT (P 5 .002). Thus, enumeration of
HLA-restricted, CMV-specific CD81 T cells
in the grafts and monitoring of these T
cells after SCT may constitute a rapid and
sensitive tool to identify SCT recipients at
risk for developing CMV disease. (Blood.
2001;98:1358-1364)
© 2001 by The American Society of Hematology
Introduction
Progressive cytomegalovirus (CMV) infection in organ and hema-
topoietic stem cell transplant (SCT) recipients is strongly related to
T-cell immunodeficiency after transplant. Recovery of cytotoxic
T-lymphocyte (CTL) activity against CMV-infected fibroblasts in
peripheral blood samples of SCT recipients is associated with
resolution of active CMV infection.1 With the use of more sensitive
culture techniques for the detection of HLA-restricted, CMV-
specific CD41 and CD81 T-cell responses, a correlation between
regeneration of CMV-specific T cells and protection from CMV
disease has been shown.2,3
The structural CMV protein pp65 has been identified as a major
source of immunodominant CTL epitopes.4,5 The fact that pp65-
specific CTLs are maintained at very high frequency in healthy
CMV carriers6 suggests that, even in immunocompetent hosts,
CMV reactivation occurs intermittently but remains subclinical
because of rapid control by the host’s immune response. Recently,
it has become possible to directly enumerate antigen-specific CD81
T cells by using so-called tetramers.7,8 Such a tetrameric complex is
formed by 4 synthetic and biotinylated peptide-loaded HLA
molecules that are centrally linked by a fluorochrome-conjugated
streptavidin molecule, which can be visualized by flow cytometry.
Here, we used HLA-A2 tetramers loaded with the immunodomi-
nant NLVPMVATV (NLV) peptide derived from pp659 to quantify
CD81, HLA-A2-NLV–specific T cells in the partially T-cell–
depleted grafts administered to HLA-A*02011 patients and to
study the kinetics of regeneration of these T cells after SCT.
Specifically, we addressed whether or not the number of trans-
planted CD81, A2-NLV–specific T cells and their kinetics of
regeneration correlated with protection against progressive CMV
infection and CMV disease.
Patients and methods
Patients
Between 1997 and 2000, 27 consecutive HLA-A*02011 (hereafter abbrevi-
ated as A2) recipients received a partially T-cell–depleted SCT from a
genotypically HLA-matched sibling or an HLA-A, B, DRB1-matched
unrelated donor (MUD) according to institutional review board-approved
protocols (Table 1). Patients were considered “standard risk” in case of a
diagnosis of acute myelogenous leukemia in first complete remission, acute
lymphoblastic leukemia in first complete remission, chronic myeloid
leukemia in first chronic phase, or untreated severe aplastic anemia. All
other diagnoses were considered high risk.
All patients were prepared for SCT by using cyclophosphamide (120
mg/kg body weight) and total body irradiation (6 Gy on each of 2
successive days with partial shielding of the lungs for a total lung dose of
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2 3 4.5 Gy). Antithymocyte globulin was administered to all 7 MUD SCT
recipients as part of the conditioning regimen to enhance immunosuppres-
sion. T-cell depletion was performed by sheep erythrocyte rosetting in 15
patients and by selection of CD341 cells in 12 patients, followed by T-cell
add-back, as to have the grafts contain 0.2 3 106 T cells/kg body weight of
the recipient. All patients received additional prophylaxis for graft-versus-
host disease (GVHD) by using cyclosporine (3 mg/kg/d) from days 23 to
1120 relative to SCT. Acute and chronic GVHD were classified according
to severity and were treated as described elsewhere,10 as was transfusion
support and prophylaxis of bacterial and fungal infections.
Diagnostic tests for CMV infection and CMV disease
CMV seropositivity was assessed by detection of immunoglobulin (Ig)M
and IgG antibodies to CMV late antigen.11 The presence of CMV-specific
IgG antibodies in healthy blood donors, in SCT donors, or in patients before
SCT was taken as a marker for CMV carrier status. CMV antigenemia was
monitored weekly in SCT recipients from days 0 to 1150 and at longer
intervals thereafter by using immunocytochemical detection of pp65
antigen in leukocytes.12 Test results were considered positive in case of 1 or
more positively stained leukocyte. Patients with a positive pp65 antigen-
emia test were monitored twice weekly until pp651 leukocytes had become
undetectable. CMV disease was diagnosed on the basis of an inflammatory
process because of CMV, confirmed either by the immediate early antigen
assay or CMV cultures, and combined with the presence of typical
cytopathic effects in histologic preparations if biopsies were available.10
Ganciclovir therapy
Preemptive ganciclovir (GCV) therapy (5 mg/kg intravenously twice daily)
was started if CMV antigenemia tests had revealed 4 or more pp651
leukocytes per test and was discontinued after 2 successive negative test
results.10 CMV disease was treated with a combination of GCV and
CMV-specific immunoglobulins.13
Enumeration of CD81 T lymphocytes binding
HLA-A2, NLV tetramers
Venous blood samples collected in sodium heparin were collected at 2, 3, 6,
9, and 12 months after SCT. As reference, venous blood samples were
obtained from 29 controls (ie, 20 apparently healthy laboratory workers and
9 SCT donors). From the latter, the blood samples were obtained before
mobilization or bone marrow donation. Absolute CD81 T-cell counts were
assessed within 6 hours after venipuncture; mononuclear cells were isolated
from the remainder of the sample, cryopreserved in medium containing
10% dimethyl sulfoxide, and stored in liquid N2. CD81 T lymphocytes were
enumerated by using a 3-color, single-platform, whole-blood immunostain-
ing technique.14 The following monoclonal antibodies were used: CD45
(clone 2D1 conjugated with fluorescein isothiocyanate [FITC]; BD Bio-
sciences [BD], San Jose, CA), CD8 (clone SK1 conjugated with phyco-
erythrin [PE]; BD) and TCR PAN a/b (clone BMA031 conjugated with
PE-Cy5; Immunotech, Marseille, France). Of each sample, 50 000 leuko-
cytes were acquired using a FACSCalibur flow cytometer (BD). During
data analysis, CD81 T lymphocytes were defined as events with low to
medium forward light scatter (FSC), low sideward light scatter (SSC),
CD451, TCRab1, and CD81.
The proportion of CD81 T cells binding HLA-A2 NLV (A2-NLV)
tetramers was assessed on cryopreserved and thawed mononuclear cell
suspensions and reference SCT samples. The A2-NLV tetramer, conjugated
with PE, was produced by Beckman-Coulter, Immunomics Division
(Marseille, France), and validated as described elsewhere.9 After thawing,
cells were incubated with A2-NLV tetramer and CD8 (clone SK1 conju-
gated with allophycocyanin). After 1 wash, cells were resuspended in
phosphate-buffered saline (PBS) containing 1 mg/mL 7-aminoactinomycin
D (Sigma, St Louis, MO). Following acquisition of 20 000 living CD81
lymphocytes (defined as having low to intermediate FSC, low SSC, as well
as being 7-AAD2 and CD81), the proportion of living CD81 T cells
binding the A2-NLV tetramer was assessed, and the absolute number of
circulating A2-NLV–specific CD81 T cells was calculated from the
proportion of CD81 T cells binding A2-NLV tetramers and the simulta-
neously obtained absolute CD81 T-cell count. Of note, the A2-NLV
tetramer-binding T cells were CD8bright and not CD8dim (Figure 1). The
lower limit of detection was 0.1% A2-NLV–specific CD81 T cell (fraction
of viable CD81 T cells) and, in absolute counts, 1 A2-NLV–specific CD81
T cell/mL blood. In the stem cell grafts, the number of transplanted
A2-NLV–specific CD81 T cells/kg body weight of the recipient was
calculated from the proportion of CD31 T cells coexpressing CD8 and
binding A2-NLV tetramers plus the simultaneously established number of
CD31 T cells/kg transplanted.
Figure 1. T lymphocytes binding the HLA-A2 NLVPMVATV (A2-NLV) tetramer
are CD8bright and not CD8dim. Following acquisition of a list mode data file containing
20 000 viable CD81 lymphocytes, viable cells were selected on the basis of 7-AAD
negativity (Gate 1). Among the viable mononuclear cells, CD81 lymphocytes were
selected on the basis of CD8 expression and a low sideward scatter signal (Gate 2).
Lymphocytes fulfilling the criteria of Gates 1 and 2 are displayed in the figure. The
percentage of A2-NLV–specific CD81 T lymphocytes was assessed and expressed
as a fraction of viable CD81 lymphocytes by using quadrant statistics. PE, phyco-
erythrin; APC, allophycocyanin.
Table 1. Patient characteristics
Patient characteristics No. of patients
Sex (male/female) 17/10
Median age, y (range) 39 (16-53)
Diagnostic indication for SCT
Acute myelogenous leukemia 9
Acute lymphoblastic leukemia 3
Chronic myeloid leukemia 5




Severe aplastic anemia 1
Risk status (standard/high) 11/16
Stem cell donor type (sibling/unrelated) 20/7
Stem cell source (bone marrow/peripheral blood) 18/9
Median no. of cells grafted (range)
Mononuclear cells 3 107/kg 1.0 (0.2-0.0)
CFU-GM 3 104/kg 26.0 (4.3-128.4)
CD31 T lymphocytes 3 106/kg 0.2 (0.2-6.4)*
CMV serology before SCT
Recipient negative, SCT donor negative 6
Recipient negative, SCT donor positive 3
Recipient positive, SCT donor negative 5
Recipient positive, SCT donor positive 13
SCT, stem cell transplant; CFU-GM, granulocyte-macrophage colony-forming
unit; CMV, cytomegalovirus.
*Sheep erythrocyte rosetting resulted in incomplete removal of the T lympho-
cytes in 2 patients (patients 1 and 6 in Table 3), who, as a result, received 6.4 and
1.6 3 106 T cells/kg. These patients received methotrexate as additional graft-versus-
host disease prophylaxis on days 1, 3, 6, and 11 after SCT.
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Statistical methods
For nonparametric statistical analyses, Wilcoxon test and Spearman rank
correlation test were used. Fisher exact test (2-sided) was used to analyze
the 2-by-2 tables. P values , .05 were considered significant.
Results
CMV serology before SCT and CMV infection
Nine patients were CMV seronegative before SCT and 3 of them
received grafts from a CMV-seropositive donor. None of these 9
patients became infected with CMV after SCT (Table 2).
Eighteen patients were CMV seropositive (Table 2); 5 of them
received SCT from a CMV-seronegative donor and all of these 5
patients reactivated their CMV as evidenced by the appearance of
pp651 leukocytes in the blood at a median of 25 days (range:
22-47) after SCT (Table 3). These 5 patients received preemptive
GCV therapy, and recurrence of CMV antigenemia required
multiple courses of GCV treatment in 4 of them. Three patients
developed CMV disease at 106, 236, and 253 days after SCT. CMV
disease was fatal in 2 of these 3 patients, who died of CMV
encephalitis (patient 4) and CMV pneumonitis (patient 5). CMV
infection involved the bone marrow in patient 3 with early-onset
disease (ie, day 106), but this syndrome resolved on treatment with
GCV and CMV-specific immunoglobulins.
Nine of 13 CMV-seropositive recipients of SCT from a
CMV-seropositive donor developed CMV antigenemia after SCT;
pp651 leukocytes became detectable at a median of 49 days (range:
17-355) after SCT (Table 3). Seven of these 9 patients received
preemptive GCV therapy, and recurrence of CMV antigenemia
required multiple courses of GCV treatment in 3 of these 7 patients.
One patient (6) developed CMV disease of the bone marrow at 38
days after SCT, which was followed by secondary graft failure;
ultimately, this patient died of CMV encephalitis despite prolonged
GCV therapy.
More preemptive treatment with GCV had to be administered to
CMV-seropositive recipients of grafts from CMV-seronegative
donors than to those of grafts from CMV-seropositive donors (3
[1-6] versus 1 [0-3] courses, respectively; P 5 .009). CMV disease
occurred more frequently after SCT from a CMV-seronegative than
from a CMV-seropositive donor (3 of 5 versus 1 of 13 patients,
respectively; P 5 .04). The higher incidence of CMV antigenemia
and disease after SCT from CMV-seronegative versus CMV-
seropositive donors indicates that CMV-specific T lymphocytes
in the graft may protect against progressive CMV infection
(see below).
Enumeration of A2-NLV–specific CD81 T lymphocytes
No A2-NLV–specific CD81 T cells were detectable in the periph-
eral blood of 8 CMV-seronegative SCT donors tested. When
expressed in absolute counts, A2-NLV–specific CD81 T cells were
above the detection limit (ie, $ 1/mL) in 21 of 29 CMV-
seropositive SCT donors or healthy laboratory workers. The
median value was 3/mL (range: , 1-46). When expressed as a
fraction of CD81 T cells, A2-NLV–specific CD81 T cells were
above the detection limit (ie, $ 0.1% of CD81 T cells) in 23 of the
29 CMV-seropositive individuals. The median value was 0.7%
(range: , 0.1%-11.3%) of CD81 T cells. The enumeration results
expressed in relative and absolute numbers were strongly and
positively correlated, both in healthy CMV-seropositive individu-
als and in SCT recipients (overall, Spearman rank correlation
coefficient r 5 0.94; Figure 2). Therefore, results are only pre-
sented in absolute numbers in the following sections.
Repopulation kinetics of A2-NLV–specific CD81
T lymphocytes after SCT
The repopulation kinetics of total CD81 T cells is shown in Figure
3 and that of the subset of A2-NLV–specific CD81 T cells in Figure
4. These data are separately shown for 9 CMV-seronegative
patients (Figure 3A, Figure 4A), in 4 CMV-seropositive patients
without antigenemia (Figure 3B, Figure 4B), in 10 CMV-
seropositive patients developing CMV antigenemia but no CMV
disease (Figure 3C, Figure 4C), and in 4 patients with CMV disease
after SCT (Figure 3D, Figure 4D). The rates of repopulation of total
CD81 T cells (Figure 3) in these 4 groups was not significantly
different, although, among patients with active CMV infection,
CD81 T-cell repopulation in the group with CMV disease (Figure
3D) lagged behind that of the group with CMV antigenemia but
without CMV disease (Figure 3C). However, differences between
these latter 2 groups became significant when A2-NLV–specific
CD81 T cells were studied (Figure 4).
A2-NLV–specific CD81 T cells remained undetectable in 8 of
the 9 CMV-seronegative patients, irrespective of whether the donor
was CMV seropositive or not. In 1 patient, A2-NLV–specific CD81
T cells just reached the detection limit (ie, 1 cell/mL) at 3 and 6
months, to become undetectable again at 9 and 12 months after
SCT (Figure 4A).
All but 1 of 14 CMV-seropositive patients without CMV
disease recovered their A2-NLV–specific CD81 T cells (ie, these
cells became detectable at 2 or more occasions). The group of 10
patients developing CMV antigenemia after SCT showed a recon-
stitution of A2-NLV–specific CD81 T cells to higher (ie, supranor-
mal) levels (Figure 4C) than the group of 4 patients without CMV
antigenemia in which A2-NLV–specific CD81 T cells stayed
within the normal range and even remained undetectable in 1 of
them (patient 16; Figure 4B).
Most strikingly, A2-NLV–specific CD81 T cells remained
undetectable throughout the entire follow-up of 3 of the 4 patients
developing CMV disease, whereas A2-NLV–specific CD81 T cells
were detected only once in the fourth patient (5) (ie, 2 cells/mL on
day 82) but were undetectable again when CMV disease developed
at day 236 (Figure 4D). Thus, CMV-seropositive SCT recipients
who developed CMV viremia but reconstituted their A2-NLV–
specific CD81 T cells had a significantly lower frequency of CMV






CMV antigenemia 0 14
Recurrent antigenemia* 0 7
CMV disease 0 4
Survival status (alive/dead) 7/2 13/5
Cause of death
Relapse of original disease 1 0
CMV disease (main cause) 0 2†
CMV disease (contributing) 0 1‡
Chronic GVHD 1 2
SCT, stem cell transplant; CMV, cytomegalovirus; GVHD, graft-versus-
host disease.
*Requiring therapy with ganciclovir.
†Death from CMV encephalitis (n 5 1) or CMV pneumonitis (n 5 1).
‡Organ affected: bone marrow.
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disease than those who did not recover such T cells (1 of 11 versus
0 of 3 patients, respectively; P 5 .01).
The following parameters did not significantly influence the
repopulation kinetics of total CD81 T cells (all 27 patients) or
A2-NLV–specific CD81 T cells (18 CMV-seropositive patients) at
the time points studied: SCT donor type (ie, sibling versus
unrelated), stem cell source (ie, bone marrow versus peripheral
blood), technique of T-cell depletion (ie, sheep erythrocyte roset-
ting versus CD341 cell selection), and donor CMV serology (ie,
positive versus negative) (data not shown).
Transfer of A2-NLV–specific CD81 T lymphocytes
with the grafts
No A2-NLV–specific CD81 T cells were detectable in the grafts of
5 CMV-seronegative donors tested (Table 3). The partially T-cell–
depleted grafts from 10 of the 13 CMV-seropositive donors tested
contained a median of 1.6 3 103 A2-NLV–specific CD81 T
cells/kg body weight of the recipient (range: 0.2-11.3), whereas
Figure 2. The percentages and absolute numbers of A2-NLV–specific CD81
T cells in peripheral blood are strongly and positively correlated. On the x axis,
the percentage of A2-NLV–specific CD81 T cells (expressed as a fraction of total
CD81 cells) is shown; on the y axis, the absolute number of A2-NLV–specific CD81 T
cells (expressed in counts per microliter). Data are from 29 blood samples of 29
healthy HLA-A*02011, CMV-seropositive SCT donors or laboratory workers (F) and
from 71 blood samples obtained from 18 HLA-A*02011, CMV-seropositive SCT
recipients (E). Overall, Spearman rank correlation test is r 5 0.94 (P , .0001).
Logarithmic scales were used for the x and y axes to compress the figure.
Figure 3. Repopulation of total CD81 T cells after allogeneic, T-cell–depleted
SCT. (A) CMV-seronegative patients (n 5 9); (B) CMV-seropositive patients without
CMV antigenemia after SCT (n 5 4); (C) CMV-seropositive patients developing CMV
antigenemia but no CMV disease (n 5 10); (D) CMV-seropositive patients develop-
ing CMV antigenemia and CMV disease (n 5 4). Logarithmic scales were used for
the y axes to compress the figure. For each patient group, the median values per time
point are connected with a line. In each panel, the upper and lower horizontal lines
indicate the 95th and 5th percentiles of 29 healthy CMV-seropositive HLA-A21
individuals, respectively. SCT, stem cell transplantation.




















1 (S) Neg 47 1 — , 0.1 14.2 (59)* 155 (90)* 365
2 (U) Neg 25 3 — , 0.1 2.1 (293) 14 (293) 365
3 (U) Neg 55 3 106 , 0.1 , 0.1 , 1 270
4 (U) Neg 22 6 253 , 0.1 0.2 (92) , 1 270
5 (S) Neg 25 4 236 , 0.1 0.2 (82) 2 (82) 238
6 (S) Pos 38 3 38 , 0.1 , 0.1 , 1 367
7 (S) Pos 49 2 — 3.5 0.7 (54) 2 (54) 181
8 (S) Pos — 0 — 11.3 3.4 (89) 17 (89) 355
9 (S) Pos 18 1 — 0.8 2.9 (346) 113 (346) 346
10 (U) Pos 17 0 — 2.2 3.3 (61) 40 (61) 181
11 (U) Pos 74 3 — 1.0 5.3 (84) 124 (358) 358
12 (S) Pos 24 1 — , 0.1 5.4 (180) 36 (180) 180
13 (S) Pos — 0 — 3.6 0.5 (59) 2 (94) 365
14 (U) Pos 143 0 — 0.8 3.8 (178) 19 (178) 339
15 (S) Pos 357 1 — , 0.1 0.2 (180) 1 (94) 370
16 (S) Pos — 0 — 0.2 0.2 (123) , 1 181
17 (S) Pos 130 1 — NT 1.3 (60) 2 (180) 180
18 (S) Pos — 0 — NT 4.3 (59) 5 (97) 270
CMV, cytomegalovirus; A2-NLV, NLVPMVATV peptide presented by HLA-A2; SCT, stem cell transplant; GCV, ganciclovir; S, HLA-matched sibling donor; U, HLA-matched
unrelated donor; NT, not tested.
*Day after SCT.
†Number of A2-NLV-specific CD81 T cells 3 103/kg body weight of the recipient.
‡Peak percentage of A2-NLV-specific CD81 T cells (expressed as fraction of total CD81 T cell); day on which peak percentage was observed (in parentheses).
§Peak absolute number of A2-NLV-specific CD81 T cells 3 103/mL; day on which peak absolute number was observed (in parentheses).
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such T cells could not be detected in the remaining 3 grafts. Of
note, 2 grafts containing 0.8 and 4.6 3 103 A2-NLV–specific CD81
T cells/kg, respectively, were administered to CMV-seronegative
recipients, who did not recover these T cells during 12 months
of follow-up.
Among CMV-seropositive patients, all 8 recipients of grafts
without detectable A2-NLV–specific CD81 T cells needed preemp-
tive GCV treatment versus 3 of 8 recipients of grafts with
detectable A2-NLV–specific CD81 T cells (P 5 .03). Furthermore,
the number of A2-NLV–specific CD81 T cells transferred with the
graft was inversely correlated with the number of preemptive GCV
treatment courses administered (r 5 20.61; P 5 .01; Figure 5).
Among CMV-seropositive SCT recipients, CMV disease occurred
in 4 of 8 patients (50%) receiving a graft without detectable
A2-NLV–specific CD81 T cells (ie, , 0.1 3 103 cells/kg), and
none of the 8 patients receiving a graft with detectable A2-NLV–
specific CD81 T cells developed CMV disease (P 5 .08).
Discussion
The use of HLA-A*0201 tetramers loaded with the CMV pp65-
derived NLV peptide enabled us to monitor CMV-specific T-cell
immunity by quantitating A2-NLV–specific CD81 T lymphocytes
in HLA-A21 recipients of an allogeneic, partially T-cell–depleted
SCT. Specifically, we studied whether or not quantification of
CMV-specific CD81 T cells in stem cell grafts and monitoring of
their rate of recovery after SCT would predict the occurrence of
progressive CMV infection and, in particular, CMV disease.
Although the number of patients in our study was small (ie, 27, of
which 18 were CMV seropositive), several of our conclusions are
supported by the recent report of Cwynarski et al15 who studied
CMV-specific T-cell reconstitution using tetramer technology in 13
recipients of non–T-depleted sibling SCT and in 11 recipients of
unrelated SCT who had undergone in vivo T-cell depletion using
the Campath 1H monoclonal antibody.
Our key findings are the following: (1) failure to recover
A2-NLV–specific CD81 T cells after SCT by CMV-seropositive
recipients developing CMV viremia was associated with the
development of CMV disease; (2) the number of A2-NLV–specific
CD81 T cells in the grafts administered to CMV-seropositive SCT
recipients is inversely correlated with the number of recurrent
CMV infections after SCT, requiring preemptive GCV treatment;
and (3) among CMV-seropositive recipients, recurrent CMV
antigenemia and CMV disease occurred significantly more fre-
quently after SCT from a CMV-seronegative than from a CMV-
seropositive donor.
Our results indicate that protection against progressive CMV
infection and CMV disease is being conferred by (1) CMV-specific
memory T lymphocytes transferred with the grafts and (2) the
development of a CMV-specific cellular immune response after
SCT. In line with our findings, Cwyniarski et al15 found that
reconstitution of CMV-specific CD81 T cells to levels more than
10 3 103/mL protected against CMV disease. These combined
results confirm earlier studies based on functional assays, ie,
cytotoxicity assays to monitor CMV-specific CD81 T cells2,3 and
lymphoproliferation assays to monitor CMV-specific CD41
T cells.3,16
With respect to early recovery of the CMV-specific immune
response, Cwynarski et al15 found, in CMV-seropositive patients,
that CMV-specific CD81 T-cells became detectable in all of 12
recipients of SCT from a CMV-seropositive donor (between 21 and
116 days after SCT), whereas CMV-specific CD81 T cells regener-
ated only in 1 of 5 recipients of SCT from a CMV-seronegative
donor (at 149 days after SCT). These data are consistent with
earlier findings, ie, that CMV-seropositive recipients of SCT from
CMV-seropositive donors regenerate their CMV-specific helper
T-cell3,17 and cytotoxic T-cell responses3 more quickly than recipi-
ents of SCT from CMV-seronegative donors. In our study, monitor-
ing was started only at 2 months after SCT, and, from that time
point onward, no significant effect of donor CMV serology on the
rate of CMV-specific CD81 T-cell reconstitution was apparent.
Remarkably, in some of our SCT recipients with CMV antigenemia
(even including one recipient of a SCT from a CMV-seronegative
donor [patient 1]), as well as in some of Cwynarski’s patients,15
CMV-specific CD81 T cells had already regenerated to levels well
above the normal range at 2 months after SCT. These results are
consistent with the hypotheses that, apart from memory T cells in
Figure 4. Repopulation of A2-NLV–specific CD81 T cells after allogeneic,
T-cell–depleted SCT. In each panel, the horizontal line indicates the 95th percentile
of 29 healthy CMV-seropositive (SCT) HLA-A21 individuals. Among CMV-
seropositive recipients with CMV antigenemia (C,D), differences in A2-NLV–specific
CD81 T-cell counts between patients without and with CMV disease were significant
between 2 and 9 months after SCT (P values between .001 and .05 using Wilcoxon
test). During that period, differences in total CD81 T-cell counts between patients
without and with CMV disease were not significant. See further the legend to Figure 3.
Figure 5. The number of A2-NLV–specific CD81 T cells transplanted and the
number of preemptive ganciclovir courses administered to the respective SCT
recipients are inversely correlated. The number of A2-NLV–specific CD81 T cells
transplanted was expressed as the number of transplanted T cells 3 103 per kg body
weight of the recipient; a logarithmic scale was used for the x axis to compress the
figure. Spearman rank correlation coefficient is 20.61 (P 5 .01). GCV, ganciclovir.
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the graft, naive T cells may mount a primary immune response
against CMV, and/or residual recipient-derived memory T cells
may contribute to the regeneration of CMV-specific T cells
after SCT.
With respect to long-term recovery of the CMV-specific im-
mune response, we observed that A2-NLV–specific CD81 T cells
reconstituted to lower levels in CMV seropositive patients without
(or with very late) CMV antigenemia as compared with those
developing CMV antigenemia early after SCT (but without CMV
disease). In addition, we did not observe regeneration of A2-NLV–
specific CD81 T cells in CMV-seronegative recipients of grafts
from CMV-seropositive donors. Again, these findings are consis-
tent with those of Cwynarski et al15 and suggest that CMV
antigenemia (ie, active CMV infection) is needed to stimulate the
expansion of A2-NLV–specific CD81 T cells. In line with these
observations, Li et al3 observed in their randomized study of GCV
versus placebo as prophylaxis for active CMV infection that GCV
prophylaxis until day 100 after SCT was associated with delayed
recovery of CMV-specific T-helper and CTL responses and sug-
gested a reduced stimulation of CMV-specific memory T cells
because of suppression of CMV replication by GCV. Although this
mechanism may also have been operational in our patients, we also
propose that a delayed recovery of CMV-specific T-cell immunity
per se, especially after SCT from a CMV-seronegative donor, may
have caused increased CMV replication and antigenemia, necessi-
tating preemptive GCV therapy.
The structural CMV protein pp65 has been identified as a major
source of immunodominant CTL epitopes,4,5 among which the
NLV peptide constitutes the major epitope presented by HLA-
A2.5,18 The fact that quantification of CD81 T cells specific for this
single peptide only, yielded already highly informative data in this
group of HLA-A21 patients emphasizes the immunodominance of
the NLV peptide in the HLA-A2–restricted immune response
against CMV. However, the NLV peptide does not stimulate CD81
T cells efficiently in all HLA-A21 CMV carriers.19 This situation
may be due to (1) the varying frequency of CTL specific for a given
peptide as a function of the HLA type of the individual and (2) the
role of other CMV-encoded proteins than pp65 as targets for the
immune response against CMV. In this context it is relevant that
CD81 CTLs specific for the CMV immediate early protein 1,
transcribed very early in the course of active CMV infection, are
found in similarly high frequencies as CTL specific for pp65, which
is a structural protein of the virion and whose expression does not
require transcription of viral DNA.19,20 These results may explain
our observation that approximately one quarter of healthy CMV-
seropositive HLA-A21 individuals had no detectable A2-NLV–
specific CD81 T cells. Also, this situation may have been the case
in our patient 7 who regenerated her A2-NLV–specific CD81 T
cells only to very low levels but did not develop CMV disease in
spite of recurrent high-level CMV antigenemia.
The advantage of flow cytometric assays over the conventional
culture-based assays such as cytotoxicity, lymphoproliferation, and
even ELISPOT assays are reduced time requirements, lower costs,
and higher accuracy and precision (ie, higher amenability to
standardization). A major restriction of tetramer-based enumeration
of antigen-specific CD81 T cells is that each combination of
peptide and presenting HLA molecule requires a unique reagent, so
that a comprehensive analysis of CMV-specific CTL would require
the use of multiple tetramers. An attractive alternative is the flow
cytometric functional evaluation of antigen-specific CD41 and
CD81 T cells by induction of intracellular cytokine after short-term
(ie, 6-18 hours) stimulation.21,22 The evaluation of patients using
protein-spanning cocktails of CMV-derived peptides (to study
CD41 T-helper cells and CD81 CTL)23 or CMV viral lysate (to
study CD41 T cells)21 may widen the applicability of antigen-
specific immune monitoring as exemplified in Cwyniarski’s15 and
our studies.
In conclusion, the absence of A2-NLV–specific CD81 T cells in
the grafts and the impaired recovery of these T cells after SCT was
associated with persistent CMV antigenemia and CMV disease in
HLA-A21, CMV-seropositive recipients of T-cell–depleted grafts
reactivating the virus. The value for individual patient management
of rapid assessments of CMV-specific immune reconstitution
should be addressed in further prospective studies. Specifically, we
envision that this strategy may enable us to identify those patients
who may benefit from preemptive therapy, in particular the
adoptive transfer of CMV-specific T lymphocytes for prevention of
late CMV disease.
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